TORONTO, Sept. 22 /CNW/ - Spectral Diagnostics Inc. ("Spectral") today
announced the addition of Mr. Guillermo Herrera to its Board of Directors. Mr
Herrera joins Mr. R. Ian Lennox (Chairman), Mr. Edward McCormack, Dr. Henry
Freisen, Mr. Gordon Peterson, and Dr. Paul Walker on the new Board that was
elected at the Company's annual general meeting on September 14, 2006.
"We are very pleased that Mr. Guillermo Herrera has joined our Board,"
stated Dr. Paul Walker, President and CEO of Spectral. "Mr. Herrera is a
seasoned, very knowledgeable executive in the global health care sector, with
broad operational and commercial experience, including specialty and hospital
pharmaceutical products. Mr. Herrera spent 24 years at Abbott Laboratories,
most recently serving as Senior Vice President, International Operations and
President of Abbott International. In 2004, Mr. Herrera joined Rosetta
Partners LLC as the Partner and Principal in charge of the private equity
division. He currently serves as President and CEO of NeoPharm, Inc. (NASDAQ:
NEOL)," added Dr. Walker.
"I am delighted to join the Board of Directors of Spectral. I see a
significant opportunity to expand the leadership position Spectral has with
its unique products, particularly in the area of Sepsis and infectious
diseases," stated Mr. Herrera.
Spectral is a developer of innovative technologies for comprehensive
disease management. Spectral provides accurate and timely information to
clinicians enabling the early initiation of appropriate and targeted therapy.
Current products include Spectral's Rapid 1(TM) West Nile Virus assay and its
FDA approved rapid diagnostic for sepsis, the EAA(TM), as well as a range of
other biological reagents. Spectral's common shares are listed on The Toronto
Stock Exchange: SDI.
Information in this news release that is not current or historically
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, the future outlook
of Spectral and anticipated events or results is assumptions based on beliefs
of Spectral's senior management as well as information currently available to
it. While these assumptions were considered reasonable by Spectral at the time
of preparation, they may prove to be incorrect. Readers are cautioned that
actual results are subject to a number of risks and uncertainties, including
the availability of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Spectral to take
advantage of business opportunities in the biomedical industry, the granting
of necessary approvals by regulatory authorities as well as general economic,
market and business conditions, and could differ materially from what is
currently expected.
%SEDAR: 00002006E
